Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America.
Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, United States of America.
PLoS Comput Biol. 2022 May 27;18(5):e1010179. doi: 10.1371/journal.pcbi.1010179. eCollection 2022 May.
Cancer is one of the leading causes of death, but mortality can be reduced by detecting tumors earlier so that treatment is initiated at a less aggressive stage. The tradeoff between costs associated with screening and its benefit makes the decision of whom to screen and when a challenge. To enable comparisons across screening strategies for any cancer type, we demonstrate a mathematical modeling platform based on the theory of queuing networks designed for quantifying the benefits of screening strategies. Our methodology can be used to design optimal screening protocols and to estimate their benefits for specific patient populations. Our method is amenable to exact analysis, thus circumventing the need for simulations, and is capable of exactly quantifying outcomes given variability in the age of diagnosis, rate of progression, and screening sensitivity and intervention outcomes. We demonstrate the power of this methodology by applying it to data from the Surveillance, Epidemiology and End Results (SEER) program. Our approach estimates the benefits that various novel screening programs would confer to different patient populations, thus enabling us to formulate an optimal screening allocation and quantify its potential effects for any cancer type and intervention.
癌症是导致死亡的主要原因之一,但通过更早地发现肿瘤,可以降低死亡率,从而在侵袭性更小的阶段开始治疗。筛查相关成本及其收益之间的权衡使得筛查对象和时间的选择成为一个挑战。为了能够对任何癌症类型的筛查策略进行比较,我们展示了一个基于排队网络理论的数学建模平台,用于量化筛查策略的收益。我们的方法可用于设计最佳筛查方案,并估算其对特定患者群体的收益。我们的方法可以进行精确分析,从而避免了对模拟的需求,并能够在诊断年龄、进展速度、筛查敏感性和干预结果的变异性的情况下,准确地量化结果。我们通过将其应用于来自监测、流行病学和最终结果(SEER)计划的数据来证明这种方法的强大功能。我们的方法估计了各种新的筛查方案将为不同的患者群体带来的收益,从而使我们能够制定最佳的筛查分配,并量化其对任何癌症类型和干预的潜在影响。